title: Clostridium difficile infection in hospitalized cancer patients in Beijing, China is facilitated by receipt of cancer chemotherapy.
abstract: The purpose of this study was to determine the presence of Clostridium difficile infection (CDI) and risk factors for infection in hospitalized patients with diarrhea in a cancer hospital in Beijing, China. A total of 277 patients with hospital-associated diarrhea (HAD) were studied of which 41 (15%) were positive for fecal C. difficile toxin A/B. For each CDI case identified, a control with HAD but negative C. difficile specimen was enrolled to look for CDI risk factors. Receipt of cancer chemotherapy occurred in 20 (49%) patients with CDI and 9 (22.0%) patients with non-CDI HAD (OR3.39, 95%CI 1.78-10.05). Median length of chemotherapy before HAD developed was 39 days for those with CDI and 22 days for patients with CDI-negative HAD (P = 0.0391). The study found that CDI is commonly seen in cancer patients in China with increasing risk for patients who receive chemotherapy.
authors.affiliation: Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
authors.forename: X H
authors.initials: XH
authors.lastname: Han
authors.forename: C X
authors.initials: CX
authors.lastname: Du
authors.forename: C L
authors.initials: CL
authors.lastname: Zhang
authors.forename: C L
authors.initials: CL
authors.lastname: Zheng
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.forename: D
authors.initials: D
authors.lastname: Li
authors.forename: Y
authors.initials: Y
authors.lastname: Feng
authors.forename: H L
authors.initials: HL
authors.lastname: DuPont
authors.forename: Z D
authors.initials: ZD
authors.lastname: Jiang
authors.forename: Y K
authors.initials: YK
authors.lastname: Shi
mesh_terms: D036002:ADP Ribose Transferases / Q000032:analysis; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001426:Bacterial Proteins / Q000032:analysis; D016022:Case-Control Studies; D002681:China / Q000453:epidemiology; D016360:Clostridioides difficile / Q000302:isolation & purification*; D003015:Clostridium Infections / Q000139:chemically induced / Q000453:epidemiology* / Q000382:microbiology; D003967:Diarrhea / Q000139:chemically induced / Q000453:epidemiology* / Q000382:microbiology; D004358:Drug Therapy / Q000379:methods; D005243:Feces / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy*; D012307:Risk Factors; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001426:Bacterial Proteins; D036002:ADP Ribose Transferases; C410164:actin-specific ADP-ribosyltransferase, Clostridium
keywords: Chemotherapy; Clostridium difficile; Epidemiology